Publications
Publications
- January 2010 (Revised August 2011)
- HBS Case Collection
Ganeden Biotech, Inc.
By: Robert C. Pozen, Dale Alan Winger and Matthew Kenneth Ahlers
Abstract
The CEO of Ganeden Biotech, a small firm with several viable probiotic products but limited resources, must decide what markets to invest in and what intellectual property strategies will best serve its immediate and longer-term business interests.
Keywords
Entrepreneurship; Investment; Intellectual Property; Market Entry and Exit; Business Strategy; Biotechnology Industry
Citation
Pozen, Robert C., Dale Alan Winger, and Matthew Kenneth Ahlers. "Ganeden Biotech, Inc." Harvard Business School Case 310-073, January 2010. (Revised August 2011.)